LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

Actinium Pharmaceuticals Inc

Open

1.6 -1.23

Overview

Share price change

24h

Current

Min

1.6

Max

1.65

Key metrics

By Trading Economics

Income

9.1M

-6.9M

Profit margin

-821.235

Employees

27

EBITDA

9.1M

-7.5M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+261.45% upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-1.2M

51M

Previous open

2.83

Previous close

1.6

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Sept 2025, 17:03 UTC

Major Market Movers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 Sept 2025, 16:49 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 Sept 2025, 16:11 UTC

Major Market Movers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 Sept 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 Sept 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 Sept 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 Sept 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 Sept 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 Sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 Sept 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 Sept 2025, 20:25 UTC

Earnings

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 Sept 2025, 20:24 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 Sept 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 Sept 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 Sept 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Sept 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 Sept 2025, 18:40 UTC

Acquisitions, Mergers, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 Sept 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 Sept 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 Sept 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 Sept 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 Sept 2025, 16:53 UTC

Earnings

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 Sept 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 Sept 2025, 16:15 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

16 Sept 2025, 16:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

16 Sept 2025, 16:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 Sept 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Sept 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 Sept 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 Sept 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

261.45% upside

12 Months Forecast

Average 6 USD  261.45%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
help-icon Live chat